Selenium Sulfide

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Selenium Sulfide
   1. Pharmacist Assessment Report
   2. Selenium Sulfide: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Selenium Sulfide: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Selenium Sulfide, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own recorded uses, not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	4
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
pityriasis simplex
pityriasis versicolor
seborrheic dermatitis
seborrheic keratosis

Australia Market Information

Licence	Product	Dosage form	Status
4452H	Selsun	Shampoo 25 mg per mL (2.5%), 125 mL	Valid

Safety Considerations

• Knowledge-graph contraindication signal: dermatitis (from drug-disease contraindication edges, not label text).
• Drug Interactions: 79 potential interactions were recorded, all with an unclassified severity level. Examples include pantoprazole, metformin, omeprazole, triamcinolone, prednisone, warfarin, simvastatin and dexamethasone. Their clinical significance is unknown, and they are unlikely to be meaningful for a topical shampoo without a systemic absorption assessment.
• For the vulvar site and for neonatal use, mucosal irritation and percutaneous absorption need specific consideration.

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---